Sweden · Delayed Price · Currency is SEK Vitrolife AB Statistics
Total Valuation
Vitrolife AB has a market cap or net worth of SEK 12.10 billion. The enterprise value is 12.90 billion.
| Market Cap | 12.10B |
| Enterprise Value | 12.90B |
Important Dates
The last earnings date was Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | May 6, 2026 |
Share Statistics
Vitrolife AB has 135.42 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 135.42M |
| Shares Outstanding | 135.42M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 63.74% |
| Float | 75.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 19.64 |
| PS Ratio | 3.52 |
| PB Ratio | 1.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 33.15 |
| P/OCF Ratio | 19.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.59, with an EV/FCF ratio of 35.33.
| EV / Earnings | -2.57 |
| EV / Sales | 3.75 |
| EV / EBITDA | 13.59 |
| EV / EBIT | n/a |
| EV / FCF | 35.33 |
Financial Position
The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.40 |
| Quick Ratio | 2.61 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 4.40 |
| Interest Coverage | -94.80 |
Financial Efficiency
Return on equity (ROE) is -46.55% and return on invested capital (ROIC) is -42.26%.
| Return on Equity (ROE) | -46.55% |
| Return on Assets (ROA) | -21.15% |
| Return on Invested Capital (ROIC) | -42.26% |
| Return on Capital Employed (ROCE) | -46.01% |
| Weighted Average Cost of Capital (WACC) | 14.03% |
| Revenue Per Employee | 2.99M |
| Profits Per Employee | -4.35M |
| Employee Count | 1,151 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 3.46 |
Taxes
In the past 12 months, Vitrolife AB has paid 127.00 million in taxes.
| Income Tax | 127.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.92% in the last 52 weeks. The beta is 2.06, so Vitrolife AB's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | -57.92% |
| 50-Day Moving Average | 128.62 |
| 200-Day Moving Average | 139.39 |
| Relative Strength Index (RSI) | 17.91 |
| Average Volume (20 Days) | 417,978 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vitrolife AB had revenue of SEK 3.44 billion and -5.01 billion in losses. Loss per share was -37.01.
| Revenue | 3.44B |
| Gross Profit | 2.00B |
| Operating Income | -4.84B |
| Pretax Income | -4.89B |
| Net Income | -5.01B |
| EBITDA | 949.00M |
| EBIT | -4.84B |
| Loss Per Share | -37.01 |
Balance Sheet
The company has 809.00 million in cash and 1.61 billion in debt, with a net cash position of -796.00 million or -5.88 per share.
| Cash & Cash Equivalents | 809.00M |
| Total Debt | 1.61B |
| Net Cash | -796.00M |
| Net Cash Per Share | -5.88 |
| Equity (Book Value) | 7.90B |
| Book Value Per Share | 58.29 |
| Working Capital | 1.48B |
Cash Flow
In the last 12 months, operating cash flow was 635.00 million and capital expenditures -270.00 million, giving a free cash flow of 365.00 million.
| Operating Cash Flow | 635.00M |
| Capital Expenditures | -270.00M |
| Free Cash Flow | 365.00M |
| FCF Per Share | 2.70 |
Margins
Gross margin is 58.05%, with operating and profit margins of -140.55% and -145.70%.
| Gross Margin | 58.05% |
| Operating Margin | -140.55% |
| Pretax Margin | -142.01% |
| Profit Margin | -145.70% |
| EBITDA Margin | 27.59% |
| EBIT Margin | -140.55% |
| FCF Margin | 10.61% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 1.23%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 1.23% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| Buyback Yield | 0.07% |
| Shareholder Yield | 1.28% |
| Earnings Yield | -41.42% |
| FCF Yield | 3.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2018. It was a forward split with a ratio of 5.
| Last Split Date | May 17, 2018 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Vitrolife AB has an Altman Z-Score of 2.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 5 |